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Abstract: Pancreatic Ductal Adenocarcinoma (PDA) is an almost incurable radio- and chemo-resistant
tumor, and its microenvironment is characterized by a strong desmoplastic reaction associated with
a significant infiltration of T regulatory lymphocytes and myeloid-derived suppressor cells (Tregs,
MDSC). Investigating immunological targets has identified a number of metabolic and cytoskeletal
related molecules, which are typically recognized by circulating antibodies. Among these molecules
we have investigated alpha-enolase (ENO1), a glycolytic enzyme that also acts a plasminogen
receptor. ENO1 is also recognized by T cells in PDA patients, so we developed a DNA vaccine
that targets ENO1. This efficiently induces many immunological processes (antibody formation
and complement-dependent cytotoxicity (CDC)-mediated tumor killing, infiltration of effector T
cells, reduction of infiltration of myeloid and Treg suppressor cells), which significantly increase the
survival of genetically engineered mice that spontaneously develop pancreatic cancer. Although
promising, the ENO1 DNA vaccine does not completely eradicate the tumor, which, after an initial
growth inhibition, returns to proliferate again, especially when Tregs and MDSC ensue in the tumor
mass. This led us to develop possible strategies for combinatorial treatments aimed to broaden
and sustain the antitumor immune response elicited by DNA vaccination. Based on the data we
have obtained in recent years, this review will discuss the biological bases of possible combinatorial
treatments (chemotherapy, PI3K inhibitors, tumor-associated macrophages, ENO1 inhibitors) that
could be effective in amplifying the response induced by the immune vaccination in PDA.
Keywords: pancreatic ductal adenocarcinoma; alpha-enolase; DNA vaccination; immunotherapy;
PI3K inhibitors; tumor-associated macrophages; chemotherapy
1. Self-Antigens Acting as Tumor-Associated Antigens (TAAs) Are Recognized by
Antibodies in PDA
The immunosurveillance theory, which establishes the ability of the immune system to recognize
and hinder the progression of a tumor, is more than a century old [1]. It has been ascertained
that only an in-depth knowledge of the various immune populations and of the mechanisms
regulating their functions has allowed this theory to be refined, leading to the well-known theory
of “immunoediting” [2]. Based on the idea of exploiting the immune system to directly fight tumor
progression, immunotherapy has thus been developed. The crucial point of effective immunotherapy
is to identify the best “tumor-associated target” and combine specific activation of the adaptive
Cancers 2018, 10, 51; doi:10.3390/cancers10020051 www.mdpi.com/journal/cancers
Cancers 2018, 10, 51 2 of 19
immune response with the defined tumor target, including strategies focused on the release from their
natural brakes (immune checkpoints), ensuring a minimal risk of eliciting autoimmunity, or limiting
immunosuppressive mechanisms.
For many years, our group has studied the relationship between tumors and the immune
system, in particularly in pancreatic ductal adenocarcinoma (PDA). It is well known that
an inflammation-associated desmoplastic reaction, typical of this kind of tumor, creates an
immune-deviated suppressive microenvironment that favors cancer progression in place of an effective
antitumor effector response [3]. In the last 10 years, we have discovered and characterized the antibody
response in PDA patients, and we have demonstrated the efficacy of the autoantibodies and related
antigens as diagnostic markers and therapeutic targets. The autoantibody response of PDA patients
reflects the complex interplay between the microenvironment and the tumor: most of the identified
targets are metabolic and cytoskeleton molecules whose expression is deregulated in PDA, which
heavily influence the overgrowth of PDA and its ability to disseminate through the extracellular matrix,
and to rewire its metabolic pathway to fuel proliferation and evade immune system patrolling.
In our first study published in 2007, we demonstrated the presence of autoantibodies in the
sera of PDA patients that could discriminate them from healthy subjects and patients with chronic
pancreatitis or other malignancies [4]. Sera from PDA patients, healthy subjects, patients with
non-PDA cancers and chronic pancreatitis patients were analyzed, and autoantibodies and the relative
antigens were identified using a SERological Proteome Analysis (SERPA) approach. The proteomes
of three human pancreatic tumor cell lines (CFPAC-1, MiaPaCa-2, and BxPC-3) were separated by
two-dimensional-electrophoresis (2-DE), and electro-transferred onto a nitrocellulose membrane. The
obtained maps were stained with sera, and the spots recognized by antibodies were identified by
mass spectrometry. By comparing the 2-DE maps of the four groups (PDA, healthy subjects, other
malignancies and chronic pancreatitis patient sera), only nine proteins were recognized by PDA
patient antibodies, namely triosephosphateisomerase 1 (TPIS), retinal dehydrogenase 1 (AL1A1),
glucose-6-phosphate 1-dehydrogenase (G6PD), elongation Factor Tu (EFTU), isocitrate dehydrogenase
(IDHC), keratin 10 (K1C10), cofilin-1 (COF1), transgelin (TAGL) and alpha-enolase (ENO1). Most of
these proteins have been demonstrated to be up-regulated in tumors. As these antigens are self-proteins,
the antibody response against them could be explained as the result of breaking self-tolerance [4].
We focused on ENO1, a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate
to phosphoenolpyruvate, but also acts as a plasminogen receptor. ENO1 is over-expressed in many
cancers, including pancreatic cancer [5–10]. Notably, we found that ENO1 induced a high frequency of
antibody responses in PDA patients [4]. However, a more specific antibody response to ENO1 in PDA
patients was observed against its phosphorylated isoforms [6]. In a second SERPA study, when sera
from PDA, non-PDA cancer, chronic pancreatitis, autoimmune disease patients and healthy subjects
were compared in terms of antibody reactivity, six isoforms of ENO1 with the same molecular weight
but different isoelectric points, were identified [6]. Four isoforms out of these six were recognized
by almost all sera, while the two most acidic isoforms were recognized by over 60% of PDA but
by only 4% of non-PDA and 9% of chronic pancreatitis patient sera, suggesting a role as a PDA
biomarker. This hypothesis was confirmed by the presence of these two isoforms in PDA, but not in
normal pancreatic tissue [6]. Mass spectrometry analysis revealed phosphorylation on serine 419 of
these two isoforms [11], and their role as biomarkers was confirmed by statistical analysis. Indeed,
autoantibodies against the two isoforms discriminated PDA patients from controls with 62% sensitivity
and 97% specificity, and combined with the tumor marker CA 19.9, they were able to ameliorate
diagnostic performance. This could be further improved by combining with autoantibodies against
Ezrin, another antigen identified in the sera of the same cohort of patients [12]. Indeed, a diagnostic
algorithm that considered Ezrin-autoantibodies and CA 19.9, and in the discordant cases, the presence
or absence of ENOA1,2-autoantibodies, had 100% sensitivity and 92.3% specificity [12]. Autoantibodies
against Ezrin appeared to be particularly important as diagnostic tools, because their presence has been
demonstrated in a pre-diagnostic cohort of patients and at the early stage of disease in two genetically
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engineered mouse models (GEM) of PDA [12]. Interestingly, the presence of autoantibodies against
phosphorylated isoforms of ENO1, but not Ezrin, correlated with a better prognosis in advanced PDA
patients [12]. In addition to a humoral response, ENO1 is also able to elicit a cellular response in PDA
patients [5]. ENO1 was able to elicit both CD4 and CD8 T cell proliferation and IFNγ production.
Importantly, ENO1 induced antitumor cytotoxic effector T cells without affecting normal cells [5].
All these data demonstrated that autoantibody characterization may lead to identifying hits, such as
ENO1 and Ezrin, which represent promising therapeutic targets in PDA. In addition, the presence of
autoantibodies to ENO1 in other cancer patients as mentioned before, renders ENO1 a good molecular
candidate target in other types of cancers too.
2. ENO1 as a Target for PDA Immunotherapy
Over the last decade, great efforts have been invested in developing approaches for eliciting
anti-tumor responses by priming a novel (or boosting an existing) immune response against tumor
cells. These have included different strategies from antibodies to vaccines, and the huge amount
of pre-clinical and clinical results have led to the approval of some of these treatments by the U.S.
Food and Drug Administration agency and the European Medicines Agency, as immunotherapy for
cancer patients.
Although immunotherapy has been widely explored for cancer treatment, PDA seems to be
unsuitable for this approach as it is considered an “immune privileged site”. This is due to a low
rate of mutations that generate neo-antigens [13], together with an immunosuppressive environment.
However, we have demonstrated the presence of anti-ENO1 autoantibodies in PDA patient sera [6] and
of anti-ENO1-specific T cells into the tumor [5,14,15]. By cloning tumor-infiltrating lymphocytes (TILs)
from both marginal and center tumor tissues of surgically resected PDA patients, we clearly obtained
a different set of ENO1-specific T cells: most patients displayed a higher number of clones with a
Th1/Th17 (IFNγ and/or IL17 producers) phenotype in the marginal tumor area paralleled by a higher
number of clones with a T regulatory lymphocytes (Treg) phenotype (FoxP3+ and IL10 producers) [14].
These results suggested the presence of antigen-specific T cells into the tumor that, unfortunately, are
frustrated in their functions by the presence of Tregs. However, analyzing peripheral T cell clones
from the same patients revealed that those having more peripheral ENO1-specific T clones were also
surviving longer [15]. Therefore, the presence of anti-ENO autoantibodies and T cells prompted us
to verify the hypothesis of eliciting a strong anti-ENO1 immune response by a DNA vaccine, able to
counteract tumor progression.
To do this, we exploited a sophisticated GEM model that spontaneously develops PDA due to the
pancreas-specific expression of a Cre recombinase that cuts off a STOP cassette before the mutated
Kras and/or TP53 genes [16]. Based on the expression of mutated Kras alone, or in combination
with mutated TP53, mice are called KC or KPC. In our setting, KC and KPC mice were vaccinated
when Pancreatic Intraepithelial Neoplasia (PanINs) lesions were already present, and they received a
total of three (KC) and four (KPC) rounds of immunization every 3 and 2 weeks, respectively. The
ENO1 vaccine induces a specific integrated humoral and cellular response that efficiently prolonged
mouse survival from 10% to 32% in the KPC and KC mice, respectively [17]. A therapeutic setting
of ENO1-DNA vaccine was also able to significantly decrease the size of well-established in situ
adenocarcinomas. Several mechanisms were demonstrated to be responsible for this effect: the
induction of anti-ENO1 antibodies, which mediated complement-dependent cytotoxicity, inhibited
tumor cell invasion [18,19] and myeloid-derived suppressor cell (MDSC) infiltration into the tumor [20];
and the expansion of Th1 and Th17 cells, which contributed—with their cytokine—to inhibit tumor
cell growth and to elicit the B cell-isotype switch. The ENO1 DNA vaccine also significantly decreased
Treg infiltration into the tumor area and increased infiltration of effector CD3 cells (Figure 1) [17].
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Figure 1. Alpha-enolase (ENO1) DNA vaccination effects in pancreatic ductal adenocarcinoma (PDA) 
mouse model. Cartoon shows the multiple effects of ENO1 DNA vaccination on the antitumor 
immune response (black arrows): activation of B cells producing anti-ENO1 antibodies (Ab) that affect 
tumor cells and myeloid-derived suppressor cells (MDSCs) invasion and endothelial adhesion 
(vessels are shown as transparent red tubes). Moreover, vaccine induces complement-dependent 
cytotoxicity (CDC) of tumor cells (grey cells) and T cells, specially Th1/Th17 cells that release IL17, 
TNFα and IFNγ cytokines. Yellow circles and cylinders indicate the complement system and the 
membrane attack complex, respectively, involved in the CDC. Circles represent cytokines; plasma cell 
(PC). 
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vaccinated mice showed B cells organized in dense aggregates that displayed a distinct structure, the 
so-called tertiary lymphoid tissue (TLT), which were not found in normal pancreases, and only 
sporadically in PDA of untreated mice or those vaccinated with an empty-vector [21]. B cells 
organized into TLT, namely CD20-TLT, were shown to correlate with a better prognosis and with a 
greater infiltration of CD8+ T cells in a cohort of 104 PDA patients. Mice orthotopically injected with 
syngeneic PDA cells, in which no TLT was observed compared to the GEM, and depleted of B cells 
by a single injection of an anti-CD20 Ab, displayed a dramatic reduction of circulating B cells as well 
as CD20-TILs. The anti-CD20 treatment induced a significant increase in genes related to T and NK 
cell recruitment, as well as genes involved in lymphoid tissue structure development and CD8+ T cell 
differentiation and maintenance. These results highlighted B cells as an essential element of the PDA 
microenvironment, and identified their spatial organization as a key regulator of their antitumor 
function [21]. 
Finally, as ENO1 overexpression occurs in almost all PDA cases, and the immune response to it 
is a common feature of PDA patients, the use of the whole ENO1 sequence like in our strategy, is 
potentially applicable to all patients without the need of personalizing therapy. ENO1, indeed, is 
different from the “neo-antigens” that represent individual tumor mutations and that require a 
personalized immunotherapy approach. This would also be an economic advantage. 
3. Novel Therapeutic Combinations with Vaccination 
As recent studies have demonstrated, targeting a single TAA does not appear to effectively treat 
tumors. However, the ENO1 DNA vaccine gave promising results and created the possibility of novel 
combinations in terms of including other TAAs (in multiple antigen vaccines) or strategies to improve 
the efficacy of the immune system “educated” by the vaccination approach. Accumulating evidence 
indicates that multiple anticancer agents, including classic chemotherapeutics as well as targeted 
compounds, stimulate tumor-specific immune responses either by inducing immunogenic cell death 
or by engaging immune effector mechanisms [22]. 
Figure 1. Alpha-enolase (ENO1) DNA vaccination effects in pancreatic ductal adenocarcinoma (PDA)
mouse model. Cartoon shows the multiple effects of ENO1 DNA vaccination on the antitumor immune
response (black arrows): activation of B cells producing anti-ENO1 antibodies (Ab) that affect tumor
cells and myeloid-derived suppressor cells (MDSCs) invasion and endothelial adhesion (vessels are
shown as transparent red tubes). Moreover, vaccine induces complement-dependent cytotoxicity
(CDC) of tumor cells (grey cells) and T cells, specially Th1/Th17 cells that release IL17, TNFα and
IFNγ cytokines. Yellow circles and cylinders indicate the complement syste and the membrane attack
complex, respectively, involved in the CDC. Circles represent cytokines; plasma cell (PC).
The crucial role of anti-ENO1 antibodies was confirmed by the observation that ENO1 vaccinated
mice showed B cells organized in dense aggregates that displayed a distinct structure, the so-called
tertiary lymphoid tissue (TLT), which were not found in normal pancreases, and only sporadically
in PDA of untreated mice or those vaccinated with an empty-vector [21]. B cells organized into TLT,
namely CD20-TLT, were shown to correlate with a better prognosis and with a greater infiltration of
CD8+ T cells in a cohort of 104 PDA patients. Mice orthotopically injected with syngeneic PDA cells,
in which no TLT was observed compared to the GEM, and depleted of B cells by a single injection
of an anti-CD20 Ab, displayed a dramatic reduction of circulating B cells as well as CD20-TILs. The
anti-CD20 treatment induced a significant increase in genes related to T and NK cell recruitment, as
well as genes involved in lymphoid tissue structure development and CD8+ T cell differentiation and
maintenance. These results highlighted B cells as an essential element of the PDA microenvironment,
and identified their spatial organization as a key regulator of their antitumor function [21].
Finally, as ENO1 overexpression occurs in almost all PDA cases, and the immune response to
it is a common feature of PDA patients, the use of the whole ENO1 sequence like in our strategy,
is potentially applicable to all patients without the need of personalizing therapy. ENO1, indeed,
is different from the “neo-antigens” that represent individual tumor mutations and that require a
personalized immunotherapy approach. This would also be an economic advantage.
3. Novel Therapeutic Combinations with Vaccination
As recent studies have demonstrated, targeting a single TAA does not appear to effectively treat
tumors. However, the ENO1 DNA vaccine gave promising results and created the possibility of novel
combinations in terms of including other TAAs (in multiple antigen vaccines) or strategies to improve
the efficacy of the immune system “educated” by the vaccination approach. Accumulating evidence
indicates that multiple anticancer agents, including classic chemotherapeutics as well as targeted
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compounds, stimulate tumor-specific immune responses either by inducing immunogenic cell death
or by engaging immune effector mechanisms [22].
In the following part of the review, we will discuss different combinatorial therapeutic strategies
to render the DNA vaccination approach more efficacious and long-lasting.
3.1. Exploiting Chemotherapy (CTX) Regimens to Increase the Effectiveness of ENO1 DNA Vaccination
PDA remains very challenging to treat, with a cure rate of just 7%. The gold standard cure is
surgical resection, which can, unfortunately, only be performed in 20% of patients [23]. Two effective
CTX regimens-gemcitabine/nab-paclitaxel and Folfirinox (a mixture of oxaliplatin, irinotecan, folinic
acid and 5-fluorouracil) have led to improved outcomes in metastatic patients, and also represent
attractive neoadjuvant treatment strategies for locally advanced disease [24]. However, significant
differences in outcomes cannot be achieved without novel strategies.
In the last 10 years, the capacity of CTX to elicit an antitumor immune response has acquired new
interest. CTX affects cancer cells through several mechanisms that generally impair cell replication,
such as DNA damage; thus, the consequent cellular stress results in cell death [25]. In addition to the
two typical processes of cell death-necrosis and apoptosis some CTX agents induce an immunogenic
cell death in which cancer cells express damage-associated molecular patterns (DAMPs), which are
detected by receptors on a variety of innate immune cells, such as macrophages and neutrophils, but
also on antigen presenting cells (APCs) (Figure 2) [26].
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including fibroblasts, immune cells and extracellular matrix (ECM), which together are active 
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PDA displays an intense desmoplastic reaction characterized by a dense network of elements,
including fibroblasts, immune cells and extracellular matrix (ECM), which together are active
components of the tumor tissue. Furthermore, considering the immune modulating effects of some
chemotherapeutic agents used in clinical practice [27,28], the combination of CTX and DNA vaccination
could potentially increase their therapeutic efficacy.
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Recent studies have suggested that neoadjuvant regimens could be immunologically more
relevant than adjuvant treatments, as this therapeutic strategy minimizes the negative impact of
tumor bulk on the potency of the antitumor immune response, and also allows CTX to modulate the
immune phenotype of residual tumor cells [29]. The limited success achieved by previous studies on
neoadjuvant therapy could be attributed to the choice of relatively less active regimens (with a tumor
response rate of less than 20%), but novel polyCTX regimens are significantly more effective [30–32],
suggesting their use in the perioperative setting as well.
CTX also seems to interfere with the mechanisms of tumor-induced immunosuppression. Low
doses of CTX decreased the number of Tregs, along with their suppressive function, in rats bearing
an established subcutaneous tumor from colon carcinoma [33]. These selective effects could be due
to the permanent tumor-induced proliferation of Tregs, which makes them more sensitive to CTX,
or their constitutive Foxp3 expression, which increases the production of proapoptotic molecules
(Figure 2) [33].
Several studies have also demonstrated the positive effect of CTX on the antitumor immune
response in PDA. In peripheral blood of advanced PDA patients, gemcitabine treatment induced an
increase of the number and percentage of CD14+ monocytes and myeloid dendritic cells (DCs) [34].
In PDA resectable patients, tumor associated macrophages (TAMs) showed a predominant M2-like
immunosuppressive phenotype (M2-TAM), and their presence at the stroma-tumor interface was
correlated to a worse prognosis, with the exception of those patients who had undergone adjuvant
CTX, as TAM density at the stroma-tumor interface was associated with a better prognosis compared
to surgical resected patients [35]. Moreover, CTX modulated the interaction between macrophages and
PDA cells in vitro, since gemcitabine synergized with the cytotoxic effect of M1-polarized macrophages
(M1-TAM) and inhibited the pro-tumor effect of M2-TAM. This was due in part to the direct effect of
gemcitabine on macrophages, which showed an increase of M1-like markers, such as IL-12 and IFNγ,
and to the downregulation of M2-like markers, such as IL-10 (Figure 2) [35].
In an orthotopic mouse model of PDA, treatment with 5-FU combined with IFNα gave rise to
a greater number of NK cells infiltrating the tumor [36]. Furthermore, NK cells isolated from these
tumors showed a higher in vitro cytotoxicity against PDA cell lines, which in turn expressed higher
levels of MHC-I molecules and NKG2D ligands, suggesting that CTX could have a potential role in
eliciting the immunogenity of cancer cells [36].
Konduri et al. combined gemcitabine treatment with a DC-based vaccine leading to the
elimination of metastasis and recurrence, and increasing the overall survival in an orthotopic
mouse model of PDA. Mice treated with the combined therapy exhibited higher levels of effector
CD8+IFNγ+CCR7+NK1.1+ T-cells in peripheral blood and, conversely, exhausted GITR+CD8+ T-cells
were decreased. Moreover, retro-orbital tumor re-challenge of surviving animals demonstrated
that only the mice that had received the combination therapy maintained the antitumor immunity
post-treatment [37].
Immunogenicity owing to CTX is based not only on the activation of the innate immune system,
the inhibition of Treg cell immunosuppression and the enhanced activation and ability of APCs in
presenting the antigens, but also on the potential antigenicity of target cancer cells [26]. During
tumorigenesis, cancer cells accumulate a series of mutations that can be recognized as non-self by the
adoptive immune system.
However, the role of CTX in promoting the formation of neoantigens or in the modification
of TAA expression levels has yet to be explored. For this reason, we are investigating—in PDA
patients—the potential effect of CTX in inducing novel TAAs or in enhancing the antigenicity of the
already established TAAs, such as ENO1, to enhance the positive effect of DNA vaccination with
the combination of CTX treatment. Of note, to confirm the feasibility of this approach, we observed
that sera from PDA patients treated with CTX displayed an increased frequency of antibodies (IgG)
that recognized several TAAs, including ENO1, which are up-regulated in PDA [38]. Interestingly,
after CTX there was a positive correlation between the increased TAA-antibody recognition and better
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survival [38]. Notably, when the recombinant form of identified TAAs was used to stimulate autologous
peripheral T cells in vitro from PDA patients before and after CTX, an increased T cell response was
observed in PDA patients after CTX treatment [38]. This data demonstrated that the analysis of the
PDA patient antibody response before and after CTX treatment was able to identify TAAs suitable for
widening the spectrum of anti-tumor immunity achievable by vaccination in conjunction with the CTX
treatment. This approach has been confirmed in preclinical studies in which we have observed that
the combination of CTX and ENO1 vaccination in GEM mice was much more efficacious in inducing
anti-ENO1 antibodies that ENO1 vaccination alone [38]. Our working hypothesis in the future is
that PDA therapies can be implemented by targeting tumor stroma and immune infiltrating cells by
selecting CTX strategies to boost the immune response (Figure 2).
3.2. Phosphoinositide 3-Kinase (PI3K) Inhibitors to Block Myeloid-Derived Suppressor Cells
PI3K regulates different pathways involved in cell survival, apoptosis, senescence, DNA repair,
angiogenesis, cellular metabolism, motility, proliferation and differentiation, and has a key role in
tumorigenesis [39–45] The PI3K lipid kinase family is divided into three classes according to their
structure and substrate specificity. Class I PI3Ks are heterodimers formed by a regulatory and a catalytic
(p110) subunit; these are further subdivided into class IA (PI3Kα, PI3Kβ, PI3Kδ) and IB (PI3Kγ),
depending on the type of regulatory subunit in the complex (p85 or p84/p101, respectively) [45]. In the
absence of activation signals, the catalytic subunit interacts with the regulatory subunit and inhibits
kinase activity, while in the presence of a specific molecule (e.g., chemokine, growth factor, cytokine),
which binds the tyrosine kinase receptor (RTK) or G protein-coupled receptor (GPCR), PI3Ks are
recruited to the membrane where p110 is exposed, and PIP2 is phosphorylated into PIP3, leading to
activation of AKT, and the regulation of different biological functions. Moreover, while class IA PI3Kα
and β isoforms are widely expressed in endothelial, epithelial and tumor cells, PI3Kδ is expressed
in T and B lymphocytes, and the class IB isoform PI3Kγ is expressed in leukocytes and especially in
myeloid cells, where it is the major PI3K isoform [46–48].
Recently, PI3K inhibitors are being used in a clinical setting, and the number of scientists involved
in this area has vastly expanded; the key discoveries that led to the molecular understanding of PI3K
signaling and function will, therefore, be discussed [48]. Notably, the growth and metastatic spread of
different types of transplanted tumors (i.e., melanoma, lung carcinoma and thymoma) in mice in which
PI3Kδ was genetically inactivated, were significantly inhibited compared to those in normal mice [49].
In addition, PI3Kδ activity has been shown to be required for the proliferation and differentiation
of suppressive inducible Treg cells, and its specific deletion in Treg cells delayed tumor growth and
prolonged the survival of mice after tumor cell challenge [49,50]. The effectiveness of pharmacological
inhibition of PI3Kδ was assessed in therapeutic conditions using a GEM model, namely KPC. This
treatment prolonged survival and reduced the incidence of metastases and other disease-associated
pathologies [49]. The relative abundance of peripheral Tregs in lymph nodes was reduced after 7
days of treatment, correlating with higher levels of CD44highCD8+ lymphocytes in the draining lymph
nodes and relatively more infiltrating CD8+ T cells in pancreatic lesions at 14 days after treatment [49].
These data indicated that therapeutic targeting of p110δ can promote immune-mediated elimination of
cancer [49,50].
PI3Kγ is expressed in human and murine tumor-associated macrophages and myeloid cells
that are responsible for the increase in a suppressive microenvironment and fibrotic reaction into the
tumor [51]. We have demonstrated that the selective genetic deletion and pharmacological inhibition of
this kinase significantly impaired the orthotopic and spontaneous PDA tumor growth and metastasis by
affecting myeloid cell functions [46]. In another study, it has been shown that both human and murine
PDAs exhibited increased PI3Kγ-dependent Bruton tyrosine kinase (BTK) activation in CD11b+/Fcγ
II/III+ myeloid cells, and that PI3Kγ inhibition, alone or in combination with gemcitabine, slowed
the progression of orthotopic tumors [52]. Tumor suppression and increased mouse survival induced
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by PI3Kγ inhibition has been directly associated with the activation of CD8+ T cells and to M2-TAM
switch into a more anti-tumoral M1-TAM phenotype (Figure 3) [46].Cancers 2018, 10, 51 8 of 19 
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Fig re . Phosphoinositide 3-Kinaseγ (PI3Kγ) inh bitor (left) and Trabectedin (right) effects on immune
cells. CD8 recruitment dependent from M1-TAM switch of TAM and MDSC after PI3Kγ inhibition
is represented. Ca pase-8 activ tion nd cyt kine production induced by Trabectedin in TAM, IFNγ
production by T cells and IL10 inhibition in Treg are shown.
Notably, elective pharmacologic targeting of PI3Kγ restores sensitivity to immune checkpoint
blockade. We demonstrated that targeting PI3Kγ, with a selective inhibitor, currently being evaluated
in a phase 1 clinical trial (NCT02637531), can reshape the tumor immune microenvironment and
promote cytotoxic T cell-mediated tumor regression, without targeting cancer cells directly [53].
Tumor stromal cells such as pancreatic stellate cells (PSCs) and immune cells create a
microenvironment that protects cancer cells through a complex interaction, ultimately facilitating their
local proliferation and their migration to different sites [54]. Activated PSCs play a pivotal role in
the development of pancreatic fibrosis, thanks to the ability of actively proliferating, migrating, and
producing ECM components, such as type I collagen, and expressing cytokines and chemokines [55].
Activation of PSCs is regulated by different key mediators of stimulatory and inhibitory signals (i.e.,
peroxisome proliferator-activated receptor-c, Rho/Rho kinase, NF-κB), mitogen-activated protein
kinases, PI3K, Sma- and Mad-related proteins, and reactive oxygen species, the targeting of which
could be of interest for developing anti-fibrosis therapy in the future [54–56]. It is very important to
demonstrate that pharmacological inhibition of PI3Kγ could also affect PSCs.
Developing strategies focused on the inhibition of myeloid cell-mediated immune suppression,
such as the use of checkpoint and/or other inhibitors can be of interest. All anti-tumor restoring
effects of PI3K inhibitors strongly suggest that small pharmacological inhibitors that target PI3Kγ or
δ isoforms or all isoforms together can be a suitable powerful combinatorial partner to enhance the
antitumor efficacy of ENO1 vaccination (Figure 4). Despite only 20% of PDA patients displaying an
increased activation of AKT/mTOR in tumor cells [57], the cited inhibitors directly impact leukocytes,
and myeloid or Treg cells in particular. Although PI3K inhibitors down-regulate AKT activation and
influence the regulation of downstream genes, included glycolytic enzymes as ENO1 [58], this will not
affect tumor cells. Therefore, there are no potential restrictions for treatable patients.
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3.3. Macrophage Targeting to Redirect Epigenetic Changes in Tumor Infiltrating Lymphocytes
It is well known that the presence of TILs is usually associated with a better prognosis [59]. In PDA
as well, the elevated number of both infiltrating CD4 and CD8 T cells was demonstrated to correlate
with a better outcome [60]. In previous studies, we have emonstrated the presence of T cells specific
for the PDA-associated antigen ENO1, both in the tumor and in the blood f PDA patients [14,15,61].
These ENO1-specific ILs were frustrated in their Th1 and Th17 effector functions by ENO1-specific
Tregs, and were much more representative in the marginal area than within the tumor, where Tregs
were ore numerous [14].
Not only Tregs but also TAMs or DSC affect the status of T cells in cancer [62]. These populations
are known to create an immune suppressive e vironment through either secretion of cytokines, such
as IL10 a d TGFβ, or expression of inhibitory molecules, such as PD-L1 [63,64], which inhibits the
activation of CD8 T cells, and induces a switch of CD4 T cells towards Th2 and Treg phenotypes [65,66].
However, the presence of mixed stimuli in the microenvironment creates conditions for reversible
changes in infiltrating cells, i cluding TILs. These modifications derive from the activation or
inhibition of signali g pathways, along wit chromati remodeling, which is highly involved in
gene transcription control. In a recent study, we compared the epigenetic profile of infiltrating T cells
in both normal and tumoral pancreata, with or without perturbation of the tumor stroma by depleting
macrophages. To this end we used Trabectedi (Yondelis™), a sponge-derived drug that bin s to
the minor groove of DNA, causing blocking of proliferating cells, and interfering with transcription
regulation and different DNA repair pathways (Figure 3) [67,68]. Trabectedin has been demonstrated
to be effective against different tumor cell lines, and to specifically target mononuclear phagocytes by
activating the caspase 8 cascade via TRAIL receptors, which are expressed in monocytes and TAMs
(Figure 3) [69,70]. We demonstrated that CD4 and CD8 T cells accumulated to a lesser extent in PDA
compared to the normal pancreas, and highly produced IL10 but not IFNγ especially CD4 and Treg
cells [71]. This was paralleled by the enrichment of H3K4me3, an active gene histone mark, at the
promoter of Il10 in sorted tumor-infiltrated CD4 T cells and Tregs. Both cell types also showed a
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decreased level of H3K27me3, a repressive mark, at the promoter of T-bet [71]; T-bet being the main
transcription factor that induces IFNγ expression in T cells [72]. When we depleted TAM by Trabectedin
treatment, TIL CD4 cells displayed a higher production of IFNγ, and much less IL10, compared to
the same population in untreated tumors (Figure 3). Again, this phenotype was confirmed by the
epigenetic profile of sorted CD4 T cells, which showed a significant enrichment of the active mark
H3K4me3 at the T-bet promoter and a decrease of H3K4me3 at the Il10 promoter [71]. In vitro analyses
of generated macrophages treated with Trabectedin, or untreated, demonstrated that 17 out of 32
cytokines/chemokines were up-regulated by the treatment, while only CCL12 was down-modulated.
Among the significantly up-regulated cytokines/chemokines were IL2, IL12, IL17 and TNFα, which
are involved in T cell activation (Figure 3) [71]. Therefore, Trabectedin before inducing death of
macrophages induces an increase in inflammatory cytokine and chemokine production, which shapes
and regulates the epigenetic landscape of specific promoters related to the activation and phenotype of
T cells. This effect renders Trabectedin, and the specific targeting of TAM, a suitable component for
combinatorial therapies, which may open new effective ways to fight PDA. Further studies are ongoing
to assess the efficacy of the combination of Trabectedin with ENO1 DNA vaccination in fighting PDA
progression (Figure 4). Trabectedin, indeed, may lead to epitope spreading thanks to its cytotoxic effect
on tumor cells, and the combined antigen-specific vaccination could enhance T cell reactivity.
Other new therapeutic strategies deploying epigenetic modulating agents also need to be
considered for PDA. Some epigenetic drugs have been already tested in PDA with promising results,
namely the inhibitor of histone methyltransferases, by Enhancer of Zeste Homolog (EZH) 2 or histone
deacetylases (HDACs) [73], but no effects on immune infiltrating cells have been described.
4. Other Immunotherapy-Based Approaches in PDA Treatment
There are other types of immunotherapy currently being tested in clinical trials for PDA, which
include whole cell, peptide, DNA transfected tumor cells, antigen pulsed-DC vaccines and monoclonal
antibody treatments.
Whole cell vaccines typically use irradiated PDA cells as immunogens. These cells have the
potential to elicit a robust immune response because they express the full repertoire of tumor-associated
antigens. Algenpantucel-L is one of the most clinically advanced and promising immunotherapies;
it is an irradiated, live combination of two human allogeneic PDA cell lines that express the murine
enzyme α-1,3-galactosyl transferase (αGT), which directs the synthesis of α-galactosyl epitopes, usually
absent in humans, and therefore has the potential to be strongly recognized by the immune system.
Algenpantucel-L causes a hyperacute rejection of such allografts in humans, which is thought to trigger
an immune response against cancer cells [74]. Another whole cell vaccine consists of irradiated tumor
cells expressing the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) named
GVAX. This caused a potent, long-lasting antitumor response requiring both CD4+ and CD8+ T cells in
the melanoma system [75]. The first peptide vaccine applied to PDA in a clinical trial was the synthetic
Ras-peptide vaccine, which was proven to be safe and induce a good immune response in longer
survivors [76,77]. Those promising results prompted the start of a clinical trial enrolling more than 100
patients, of which no results are available, unfortunately. Other peptide vaccines investigated in clinical
trials with PDA patients include the telomerase peptide vaccine (GV1001) [78], the carcinoembryonic
antigen (CEA), alone or in combination with mucin-1 (MUC-1). The CEA antigen has been triggered
through a combination with a poxvirus-based vaccine containing three T-cell costimulatory molecules
(TRICOM): B7-1 (CD80), intracellular adhesion molecule 1 (ICAM 1) and leukocyte function associated
antigen-3 (LFA-3), while MUC-1 through a different viral-expressing vaccine (PANVAC-V, vaccinia
virus, to immunize and PANCAV-F, fowl-pox virus, to boost) in combination with GM-CSF. No clinical
benefits, however, were reported over canonical chemotherapy [79]. CEA and MUC-1 antigens were
also used to pulse DC purified from patients and re-infused after in vitro expansion and loading. Both
these DC-based vaccines were demonstrated to be safe, well-tolerated and elicited remarkable T cell
responses [79,80]. MUC-1 mRNA-transfected autologous DC were used to vaccine unresectable or
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recurrent PDA patients in combination with gemcitabine and IL2 to expand cytotoxic T cells. The
median survival appeared longer than that of patients receiving gemcitabine alone and only 5 out of 35
patients with no liver metastasis before treatment, did show metastasis after treatment [81]. Mesothelin
is another interesting antigen that has been initially characterized in ovarian cancer and PDA [82]. CD8
T cell reactivity to mesothelin was described in PDA patients receiving GVAX and cyclophosphamide,
either with or without live attenuated-Listeria monocytogene-expressing mesothelin [83]. Since 2014 at
least five new clinical trials with mesothelin-chimeric antigen receptor (CAR) T cell adoptive therapy
started (ClinicalTrials.gov identifier: NCT02159716, NCT01583686, NCT01897415, NCT02580747 and
NCT02465983), as well as with CEA and MUC-1 CAR T cells (NCT02349724, NCT02416466 and
NCT02587689 respectively). Phase I clinical trials were also performed with Wilms tumor (WT-1)
peptide-based vaccine in combination with gemcitabine [84] and Cancer testis (CT) peptide-based
vaccine in combination with vascular-endothelial growth factor receptor (VEGF-R1) and 2 (VEGF-R2)
proteins, in which clinical benefits were observed even if in a trial with few patients [85].
Beside the immunotherapeutic strategies based on vaccinations, in recent years the potential
role of immune checkpoint inhibitors in cancer treatment has become a field of great interest. The
immune checkpoint molecules, such as CTLA-4 and PD-1, are expressed on the surface of activated
T cells and their ligands, CD80/CD86 and PD-L1 respectively, are expressed mostly on APCs.
The ligand-receptor interaction leads to the interruption of the inflammatory immune response
and many tumors, including also PDA, express immune inhibitor molecules, such as PD-L1, to
evade natural anti-tumor immunity [86]. The effectiveness of the use of checkpoint inhibitor to
potentiate the anti-tumor T cell response and proliferation in several types of cancers has already been
shown [87]. To date, inhibition of the PD-1/PD-L1 axis has produced impressive response rates in
various malignancies, such as metastatic melanoma [88], renal [89] and non- small cell lung cancer
(NSCLC) [90]. The tumor microenvironment of resected pancreatic cancer patients is rich in immune
inhibitory molecules and the high expression of those molecules together with TILs is associated with
better survival [86]. Despite some contrasting reports correlating PD-L1 expression with a poorer
prognosis [91], the overall knowledge on the role of this pathway in PDA is still limited. Indeed, unlike
the responses obtained in PD-1/PD-L1 clinical trials in other cancers, no objective responses were seen
in a limited number of PDA patients with a single treatment [92]. Multiple PD-1 and PDL-1 inhibitors
alone or in combination with chemotherapy are under investigation but without reported results to
date (ClinicalTrials.gov identifier: NCT02988960, NCT02309177, NCT02331251, NCT02715531) [93].
Due to the poor success of single agent checkpoint inhibition, different approaches were integrated
including dual checkpoint blockade and multi-modality immunotherapy or traditional therapy [93].
Combined immunotherapy strategies consisting in CTLA-4 blockade and GVAX, has already displayed
benefit in a phase I study versus anti-CTLA-4 alone, with a median overall survival (OS) of 3.6 vs. 5.7
months and one year OS of 7% vs. 27% [94]. Considering the increased benefits of multi-combined
therapy in comparison to single agent treatment in PDA, together with the promising preclinical
results [95], immune checkpoints blockade could also be associated to TAAs vaccination. The observed
anti-tumor immune activity elicited by ENO1 vaccination [17], indeed, could be potentiated and
prolonged through the disruption of the tumor induced inhibitory brake (Figure 4).
5. ENO1 as Metabolic Target in Cancer Treatment
Recent evidence has shown that ENO1, in addition to its well characterized glycolytic functions,
plays a role in pathophysiological processes; for example, by using an alternative stop codon, ENO1
can be translated into a 37kDa protein, named c-myc promoter-binding protein 1 (MIP1), which is a
nuclear protein and able to bind the c-myc P2 promoter to negatively regulate transcription of this
oncogene [96]. Although ENO1 is expressed in most of cells, its gene is not considered a housekeeping
gene since its expression varies according to the pathophysiological, metabolic or developmental
conditions of cells [97]. Specifically, ENO1 translation is upregulated during cellular growth, but barely
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detectable during the quiescent phase [98,99]. Indeed, numerous reports have shown an upregulation
of ENO1 in several cancer types [100–102].
Knockdown of ENO1 in different tumor cell lines has led to a strong increase in their sensitivity
to microtubule-targeted drugs (e.g., vincristine and taxanes), due to ENO1-tubuline interactions
and also suggests a role for ENO1 in the microtubule network [103]. This effect seems related to
the drastic reduction in invasiveness, e.g., in follicular thyroid carcinoma cells [104]. Likewise,
ENO1 overexpression has been associated with poor clinical outcome in patients with head and
neck cancer, and exogenous ENO1 expression promoted cell proliferation, migration, invasion and
tumorigenesis [105]. Gene network analysis has also identified desmin, interleukin 8 and ENO1 as key
elements for colon cancer tumorigenesis [106].
The role of ENO1 in PDA has been extensively documented, and ENO1 has been shown to
promote cellular metabolism in anaerobic conditions, and drive tumor invasion through plasminogen
activation and ECM degradation [107].
During tumor formation and expansion, tumor cells increase glucose metabolism [108]. Consistent
with this, overexpression of glycolytic genes has been found in a variety of human cancers, including
PDA [4,6,109]. ENO1 is one of the leading regulators of the Warburg effect and thus plays a major
role in carcinogenesis and tumor maintenance [110]. ENO1 silencing in tumor cells decreased their
proliferation and also affected in vivo tumor growth [110,111]. Interestingly, ENO1-silenced cells were
able to resist glycolytic shutdown by rescuing oxidative phosphorylation. In the absence of ENO1, the
decrease in lactate production and increase in ATP demand promoted glucose uptake and eventually
led to the accumulation of intermediate glycolytic metabolites. Therefore, the excess of intracellular
glucose was redistributed towards alternative pathways, such as the polyol pathway (PP) and the
pentose phosphate pathway (PPP) to support cell growth and survival [110]. As demonstrated by the
use of the PPP inhibitor, namely DHEA, NADPH oxidase hyper-activation was a consequence of the
increased PPP flux and further contributed to the synthesis of superoxide. Moreover, reactive oxygen
species (ROS) were responsible for the induction of senescence and growth arrest in ENO1-silenced
cells [110,112]. We also observed that ENO1 silencing promoted catabolic pathway adaptation and
fueled the TCA cycle by anaplerotic reactions of tyrosine and glutamine catabolism, another important
molecule for PDA metabolic adaptation [113].
The above considerations led to the hypothesis of targeting ENO1 to simultaneously disturb
cancer cells in multiple ways. An interesting report by Jung et al. described a different cell
permeable glycolysis inhibitor (AP-III-a4) able to bind the outer active site of ENO1 hence dubbed
“ENOblock” [114,115]. However, it was reported that ENOblock is not able to inhibit ENO1 activity
in vitro [116]. Fortunately, there are four compounds classified as non-mutagenic and non-carcinogenic,
with a steady interaction with ENO1 that were comparable, or even superior, to the currently available
inhibitors: AEP, PhAH, and SF-2312. These compounds, namely ZINC1304634, ZINC16124623,
ZINC1702762, and ZINC72415103, may be considered promising for further development of ENO1
inhibitors, and could help fight cancer metabolically [117].
Given the complex metabolic switch with variable changes in expression of enzymes in pancreatic
cancer, altering expression levels of ENO1 with metabolic inhibitors has shown an encouraging
effect [118]. To date, there are no clinical trials involving metabolic inhibitors in PDA. However, there
has been good progress in using metabolic inhibitors in cell types other than PDA, which have proven
to have good translationability [119,120].
6. Conclusions
Having established that immunological targeting of ENO1 by DNA vaccination is a powerful
stimulus for humoral and cellular responses against PDA (Figures 1 and 4), the next generation of
immunotherapy will take advantage of recent data on the effects of chemotherapy to extend and
amplify the immune response against ENO1 and predispose the immune system to promptly respond
to ENO1 and other TAAs, as well as data demonstrating the effectiveness of the inhibition of PI3K
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isoforms to unleash antitumor responses in PDA. In addition, Trabectedin has proven to be effective in
depleting tumor-associated macrophages that infiltrate PDA and epigenetic reprograming TILs into
antitumor effector cells. Finally, ENO1 inhibition may contribute to reducing the proliferative and
invasive ability of PDA cells and to inducing their senescence. As all these approaches utilize drugs
or compounds that are used or already approved for clinical purposes, they represent an evaluable
springboard for developing—in a short time—a more efficacious protocol for the next generation of
PDA immunotherapy based on DNA vaccination (Figure 4).
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